The COMMENCE trial: 2-year outcomes with an aortic bioprosthesis with RESILIA tissue†
Authors:
Open Access
- 10 June 2017
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 52 (3) , 432-439
Abstract
The COMMENCE trial was conducted to evaluate the safety and effectiveness of a novel bioprosthetic tissue for surgical aortic valve replacement (AVR). Patients underwent clinically indicated surgical AVR with the Carpentier-Edwards PERIMOUNT™ Magna Ease™ aortic valve with RESILIA™ tissue (Model 11000A) in a prospective, multinational, multicentre (n = 27), single-arm, FDA Investigational Device Exemption trial. Events were adjudicated by an independent Clinical Events Committee; echocardiograms were analysed by an independent Core Laboratory. Between January 2013 and February 2016, 689 patients received the study valve. Mean age was 67.0 ± 11.6 years; 71.8% were male; 26.3% were New York Heart Association Class III/IV. Mean STS PROM was 2.0 ± 1.8 (0.3–17.5). Isolated AVR was performed in 59.1% of patients; others had additional concomitant procedures, usually CABG. Thirty-day outcomes for all patients included all-cause mortality 1.2%, thromboembolism 2.2%, bleeding 0.9%, major paravalvular leak 0.1% and permanent pacemaker implantation 4.7%. Median intensive care unit and hospital length of stay were 2 (range: 0.2–66) and 7 days (3.0–121.0), respectively. At 2 years, New York Heart Association class improved in 65.7%, effective orifice area was 1.6 ± 0.5 cm2; mean gradient was 10.1 ± 4.3 mmHg; and paravalvular leak was none/trivial in 94.5%, mild in 4.9%, moderate in 0.5% and severe in 0.0%. One-year actuarial freedom from all-cause mortality for isolated AVR and for all patients was 98.2% and 97.6%, respectively. Two-year actuarial freedom from mortality in these groups was 95.3% and 94.3%, respectively. These data demonstrate excellent early safety and effectiveness of aortic valve replacement with a novel bioprosthetic tissue (RESILIA™). clinicaltrials.gov: NCT01757665.Keywords
This publication has 28 references indexed in Scilit:
- Very long-term outcomes of the Carpentier-Edwards Perimount aortic valve in patients aged 50–65 yearsEuropean Journal of Cardio-Thoracic Surgery, 2015
- Very Long-Term Outcomes of the Carpentier-Edwards Perimount Aortic Valve in Patients Aged 60 or YoungerThe Annals of Thoracic Surgery, 2015
- Very Long-Term Outcomes of the Carpentier-Edwards Perimount Valve in Aortic PositionThe Annals of Thoracic Surgery, 2015
- Trends in Aortic Valve Replacement for Elderly Patients in the United States, 1999-2011JAMA, 2013
- Type 2 Diabetes Mellitus Is Associated With Faster Degeneration of Bioprosthetic ValveCirculation, 2012
- Aortic valve surgery: Marked increases in volume and significant decreases in mechanical valve use—an analysis of 41,227 patients over 5 years from the Society for Cardiothoracic Surgery in Great Britain and Ireland National databaseThe Journal of Thoracic and Cardiovascular Surgery, 2011
- Epidemiology of valvular heart disease in the adultNature Reviews Cardiology, 2011
- Aortic valve replacement with the Mitroflow pericardial bioprosthesis: Durability results up to 21 yearsThe Journal of Thoracic and Cardiovascular Surgery, 2008
- Burden of valvular heart diseases: a population-based studyThe Lancet, 2006
- Calcification of Tissue Heart Valve Substitutes: Progress Toward Understanding and PreventionThe Annals of Thoracic Surgery, 2005